Novocure's Optune Pax approved in Japan for pancreatic cancer
Japan's MHLW approved Novocure's Optune Pax for unresectable, locally advanced pancreatic cancer, delivering a significant milestone for the company's therapy platform.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed